Press Release
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer
–News Direct–
By Kyle Anthony, Benzinga
Theriva Biologics (AMEX: TOVX) is an immuno-oncology company developing oncolytic viruses, otherwise known as cancer cell-infecting viruses, to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. As a company engaged in developing differentiated clinical-stage therapeutics, Therivas mission is to change patient outcomes by working to improve the current standard of care and transform the cancer therapy landscape.
The firms management and scientific advisory board is comprised of determined and experienced leaders who are committed to offering patients with difficult-to-treat cancers the chance of a longer life. The company recently achieved a significant milestone as the U.S. FDA granted Fast Track Designation (FTD) to its candidate VCN-01 to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of pancreatic ductal adenocarcinoma (PDAC).
Company Background
Founded in 2001 and operating as Synthetic Biologics from 2012, the company was previously focused on developing biologic and drug candidates for various indications, including infectious diseases and gastrointestinal disorders. The company rebranded to Theriva Biologics in September 2022 to reflect its evolving focus on oncolytic viruses and cancer therapies. Regarding the impetus behind the firms rebranding, Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, said, The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncolytic viruses optimized for IV administration. We continue to build on the incredible progress made to date and are diligently advancing our oncolytic adenovirus pipeline. This includes lead clinical-stage program VCN-01, designed to break down the tumor stroma, and preclinical-stage program VCN-11, leveraging our proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. These two differentiated programs are intended to improve the anti-tumor effect of the oncolytic virus, co-administered chemotherapies and/or immuno-oncology therapeutics. Together, VCN-01 and VCN-11 position Theriva at the forefront of oncolytic virus development. We are excited about Therivas path towards strategic growth, renewed corporate strategy and remain on track to deliver on upcoming value-driving milestones.
Theriva Biologics Pipeline
As Steven A. Shallcrosss preceding quote suggests, Theriva Biologics' leading clinical-stage program, VCN-01, has displayed promise as a treatment solution. Presently, VCN-01 is part of an ongoing phase 2 clinical trial, entitled VIRAGE, where it is being tested in combination with standard-of-care chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. VCN-01 was also administered with the checkpoint inhibitor durvalumab (an FDA-approved immunotherapy for cancer) in a phase 1 study in patients with head and neck cancers and is currently being evaluated in combination with huCART-meso cells cells manufactured using a patients own white blood cells, which are modified to target cancer cells or cells that help cancer to grow in an investigator-sponsored study in patients with either pancreatic cancer or ovarian cancer.
Beyond VCN-01, Theriva Biologics is also developing SYN-004 (ribaxamase), which is aligned with the companys oncology focus and seeks to mitigate adverse outcomes for patients who will undergo bone marrow transplant (allogeneic hematopoietic cell transplantation) to treat hematologic cancers. 80% to 90% of these patients will be treated with an intravenous -lactam antibiotic, and this antibiotic treatment has been strongly associated with increased incidence and severity of acute graft-vs-host disease (aGVHD), vancomycin-resistant Enterococci (VRE) infection and Clostridioides difficile infection (CDI). Preventing one or all of these outcomes by SYN-004 co-administration may significantly improve treatment outcomes and reduce patient mortality.
VCN-01 Receives Fast Track Designation By The U.S. FDA
Theriva Biologics achieved a significant milestone as the FDA granted Fast Track Designation (FTD) to VCN-01. This designation, in combination with gemcitabine and nab-paclitaxel standard-of-care chemotherapy drugs is aimed at improving progression-free survival and overall survival in patients with metastatic pancreatic cancer. This recognition underscores Theriva Biologics' commitment to advancing cancer treatment and the potential of VCN-01 in this field.
Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other parts of the world is one of the factors driving the need for drugs used in its treatment. According to research published by Fortune Business Insights, the global pancreatic cancer treatment market size was $2.86 billion in 2023 and is projected to grow from $3.30 billion in 2024 to $10.69 billion by 2032.
Attaining FTD is a seminal achievement for pharmaceutical drug companies, as the designation is designed to help treatments reach patients faster by facilitating the development and expediting the review of therapies with the potential to treat serious conditions and fill an unmet medical need. Benefits of FTD to programs include early and frequent interactions with the FDA during the clinical development process, and if relevant criteria are met, the FDA may also review portions of a marketing application before the sponsor submits the complete application.
Regarding Theriva Biologics receiving the FTD, Shallcross said, The FDAs decision to grant FTD to VCN-01 highlights the urgent need for new treatment options for PDAC, which accounts for the 4th highest cause of cancer-associated deaths in the US and Europe. VIRAGE, our Phase 2b trial evaluating VCN-01 in metastatic PDAC continues to progress, with enrollment expected to be completed in the third quarter of 2024. FTD is an important step that furthers our ability to expedite the review of and build upon the compelling clinical data that underscores VCN-01s multiple modes of action and therapeutic potential in combination with chemotherapy or immunotherapy. We will continue to deliver on our mission to advance new therapeutic options for these patients.
Based on the strength of the science and its relevance, VIRAGE was accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, from May 31-June 4.
The Path Forward
Theriva Biologics' approach to cancer treatment differentiates it from its peers, potentially placing the company in a unique market position. As incidences of pancreatic cancer continue to rise globally, drug treatment options, such as VCN-01, will likely rise in demand. With VCN-01 receiving FTD from the U.S. FDA, this milestone speaks to the drug's efficacy and long-run potential. As such, the benefit that Theriva Biologics provides and the value proposition the firm espouses could continue to grow and have increased industry resonance.
Featured photo by National Cancer Institute on Unsplash.
Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/theriva-biologics-receives-fast-track-designation-from-fda-for-vcn-01-for-treating-metastatic-pancreatic-cancer-427600911
Benzinga
COMTEX_453481266/2655/2024-06-07T08:44:04
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Little Symphony is a Canadian music collective that creates ambient nature music by composing original instrumentals with authentic nature field recordings from around the world. With a catalog of over 90 albums and as a global leader in the genre, Little Symphony provides music designed to support wellness journeys, facilitate mindfulness, and foster a deeper connection to the natural world.
Canada, 17th Jun 2025 – It begins with a simple idea: the world makes its own beautiful music, if only we took a moment to connect and listen. This concept is at the core of Little Symphony, a Canadian team of devoted creatives that travels the globe to capture the Earth’s diverse soundscapes. They then accompany these authentic field recordings with their own original, ambient music to create powerful compositions for wellness and mindfulness.
This mission to amplify nature’s music to facilitate mindfulness and support listeners’ wellness journeys has deeply resonated in a world seeking tranquility and nature connection. The result is a staggering achievement with Little Symphony’s music getting streamed over one billion times on music streaming platforms such as Spotify in the last 4 years. The community has grown to over 1.2 million monthly listeners, many of which have made Little Symphony a key part of their daily lives. For some dedicated listeners, their music is more than just a playlist. Little Symphony’s music is a means to fall asleep, a soundtrack for focused work, and a tool to combat the stress of modern life.
The project’s origin is as interesting as the sounds they record. Little Symphony was started by an engineer and a physicist during their time in university. With their demanding university studies, childhood friends Bryson Huculak and Peter Macfarlane sought a creative outlet inspired by the serene landscapes of their home province of Alberta. Spoiled for choice with the diverse landscapes the province offered, Little Symphony’s co-founders began recording and composing, turning their personal wellness journey into a shareable experience. What started as a grassroots passion project in 2017 has since grown into a dedicated team of seven, committed to expanding their library of sounds from diverse locations from within Canada and across the globe.
“I think if you were to stop and listen, and I mean really listen, away from the crowds and the cars, you’d begin to notice a Little Symphony all around you,” says a representative of the group. This philosophy has held through for their entire catalog, which now features over 90 albums recorded across 16 countries, from the lush jungles of South America to the majestic cliffs of Australia. By making these environments accessible to all, Little Symphony fosters a global community united by a love for nature and a pursuit of wellness.
As they continue to lead the ambient nature genre, Little Symphony will grow its global community, forge deeper partnerships with wellness and conservation non-profits, and set a course to capture field recordings from every continent on Earth.
Media Contact
Organization: Little Symphony Inc.
Contact Person: Brianna Tejada
Website: https://www.littlesymphony.ca/
Email: Send Email
Country:Canada
Release id:29251
The post Meet Little Symphony – The Canadian Collective Leading the Ambient Nature Music Genre appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Cheshire United, United Kingdom, 17th Jun 2025 – You can mine without mining machines, electricity bills, or technical knowledge!Bitcoin prices have soared, but traditional mining is costly and has high barriers to entry? In 2025, cloud mining has become the first choice for global investors! Bow Miner allows you to mine Bitcoin, Dogecoin and other cryptocurrencies with one click without purchasing equipment or maintaining mining machines, and automatically deposits money into your account every day to create a stable passive income!
The choice of 3 million users worldwide: Bow Miner – a safe, efficient and compliant cloud mining platform
Why choose Bow Miner?
1. FCA compliance supervision
Certified by the UK Financial Services Authority, funds are transparent and safe.
2. Zero hardware investment
No mining machine is required, no electricity bills to worry about, AI intelligently optimizes income
3. Daily automatic settlement
Profits arrive in 24 hours, you can withdraw or continue to invest at any time
4. Military-grade security protection
Work with McAfee® and Cloudflare® to protect assets from hacker attacks
5. Carbon neutral mining
100% clean energy, environmentally friendly and profitable
6. Fund security, multiple protections
Bow Miner adopts the “Collagen Asset Protection Mechanism” (cold and hot wallet isolation + dynamic risk control + encrypted channel) to ensure that your assets are safe!
How to start using Bow Miner?
Start mining in 3 steps and earn cryptocurrency easily!
1. Register an account
Visit Bow Miner, click Register, enter your email address, create an account for free and get a $15 reward.
2. Choose your favorite contract
The platform offers a variety of contracts for you to choose from to meet all budgets and goals
3. Wait for income
AI automatic mining, 24-hour income arrival
Mining revolution: Let everyone easily own cryptocurrency
Bow Miner is not only a platform, but also a financial democratization movement! We break the high cost barriers of traditional mining, so that ordinary people can also enjoy the value-added dividends of Bitcoin.
Join now and seize the wealth opportunity of Bitcoin mining after-sleep income in 2025!
For more information about Bow Miner, please visit the official
website:https://88miner.net/
or contact the official email of the platform: info@88miner.com
Media Contact
Organization: Bow Miner
Contact Person: Shakespeare William
Website: https://88miner.net/
Email: Send Email
City: Cheshire United
Country:United Kingdom
Release id:29141
The post Bow Miner Innovative cloud mining model leading the new era of Bitcoin appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Founded in 2019, Air Tolentino is a locally owned and operated HVAC company providing reliable heating, ventilation, and air conditioning services across Northeast Florida. With a mission rooted in integrity and customer care, Air Tolentino continues to grow without losing the personalized touch that sets them apart.
Orange Park, FL, United States, 17th Jun 2025 – After five years of quietly becoming one of Northeast Florida’s most trusted HVAC service providers, Air Tolentino is stepping into the spotlight—ready to expand and serve even more homes and businesses across Orange Park and beyond.
Led by owner Mark Tolentino and HVAC veteran Kris Latuch, Air Tolentino has built its reputation solely through word-of-mouth referrals, offering fast, honest, and family-style service with no gimmicks or sales pressure. Now, with plans to launch subscription maintenance services, open a dedicated Orange Park location, and potentially expand into commercial HVAC, the team is turning up the heat.
“We’ve always focused on treating people like family,” said Kris Latuch, who’s served alongside Mark for the past three summers. “Now we’re ready to bring that same energy to more customers, without sacrificing the quality that’s gotten us this far.”
Air Tolentino serves:
- Orange Park
- Jacksonville
- Fleming Island
- St. Augustine
- Ponte Vedra Beach
- and surrounding areas
Whether it’s emergency AC repair, routine maintenance, or a complete system overhaul, Air Tolentino is committed to keeping Florida cool—one home at a time.
Media Inquiries & Interviews:
Mark Tolentino
(904) 314-4564
https://airtolentino.com/
6625 Argyle Forest Blvd #4
Jacksonville, FL 32244
Media Contact
Organization: Air Tolentino
Contact Person: Kris Latuch
Website: https://airtolentino.com/
Email: Send Email
Contact Number: +19043144564
Address:6625 Argyle Forest Blvd #4
City: Orange Park
State: FL
Country:United States
Release id:29249
The post Orange Parks Best-Kept Secret in AC Repair Is Ready to Make Noise Meet Air Tolentino appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Bow Miner Innovative cloud mining model leading the new era of Bitcoin
Meet Little Symphony – The Canadian Collective Leading the Ambient Nature Music Genre
Orange Parks Best-Kept Secret in AC Repair Is Ready to Make Noise Meet Air Tolentino
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
-
Press Release3 days ago
Dallas Agency Breaks Industry Norms with Risk-Free Reputation Management Trial for Small Businesses
-
Press Release1 week ago
InnoTek Computer Consulting Empowers Businesses in Bethlehem PA with Reliable IT Support and Strategic Technology Services
-
Press Release4 days ago
Querv Exchange Upgrades Web Platform with Multilingual and Intelligent Navigation
-
Press Release7 days ago
Dr Yahia Ananes Metabolic Protocol Offers New Integrative Strategy for Chronic Illness and Cancer Support
-
Press Release2 days ago
Coinsult Sets the Standard in Smart Contract Audits With Proven Track Record and Introduces New Dashboard
-
Press Release7 days ago
Driven by RWA and AI, NPC leads the new era of crypto finance
-
Press Release1 week ago
Bitnile.com, a Subsidiary of Hyperscale Data, Now Accepts Nile Coin for Social Casino Gaming
-
Press Release1 week ago
BingX and Chelsea FC Unveil 25/26 Training Kit with “Trained on Greatness” Campaign